Palabras clave
Cómo citar
Resumen
El sarcoma fibroblástico mixoinflamatorio es una neoplasia rara, típicamente localizada en la porción distal de las extremidades (manos y pies), que clínicamente se presenta como una masa indolora de crecimiento lento. Microscópicamente, la proporción variable de sus distintos componentes (fusocelular, inflamatorio, células gigantes bizarras multinucleadas y componente mixoide) hace que puedan plantearse diagnósticos diferenciales muy dispares, desde un proceso inflamatorio-infeccioso a uno linfoproliferativo o una neoplasia sarcomatosa. Presentamos el caso de una mujer de 53 años con un nódulo subcutáneo escapular y sus distintos diagnósticos diferenciales histológicos.
Citas
Montgomery EA, Devaney KO, Giordano TJ, Weiss SW (1998) Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin’s disease, and various sarcomas. Mod Pathol 11:384–391.
Meis-Kindblom JM, Kindblom LG (1998) Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol 22:911–924.
Michal M. Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol Res Pract 1998; 194 (8): 529.
Numminen J, Bizaki A, Kujansivu J, Huovinen S, Rautiainen M. Myxoinflammatory fibroblastic sarcoma of the nose: first reported case at an unusual location (nasal dorsum), with a review of the literature. Ear Nose Throat J. (2016) 3:E32–5.
Auw-Haedrich C, Mentzel T, Reinhard T. Myxoinflammatory fibroblastic sarcoma of the iris. Pathology. (2017) 7:794–5.
Jain E, Kini L, Alaggio R, Ranganathan S. Myxoinflammatory fibroblastic sarcoma of eyeball in an infant: a rare presentation. Int J Surg Pathol. (2020) 3:306–9.
Wei C, Yang X, Guo P, Chen X, Li C, Chen J, et al. Myxoinflammatory fibroblastic sarcoma of the parotid gland: First case report and literature review. Front Med (Lausanne). 2022; 9.
McFarlane R, Meyers AD, Golitz L. Myxoinflammatory fibroblastic sarcoma of the neck. J Cutan Pathol. 2005 May;32(5):375-8.
BlueBooksOnlineWho.int. https://tumourclassification.iarc.who.int/chaptercontent/64/244.
Laskin WB, Fetsch JF, Miettinen M. Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome. Am J Surg Pathol. 2014 Jan; 38(1):1-12.
Sakaki M, Hirokawa M, Wakatsuki S, Sano T, Endo K, Fujii Y et al (2003) Acral myxoinflammatory fibroblastic sarcoma: a report of five cases and review of the literature. Virchows Arch 442:25–30.
Kurmar S, Lefkowitz RA, Neto AD (2017). Myxoinflammatory fibroblastic sarcoma: clinical, imaging, management and outcome in 29 patients.
Hassanein, A.M., Atkinson, S.P., Al-Quran, S.Z., Jain, S.M. and Reith, J.D. (2008), Acral myxoinflammatory fibroblastic sarcomas: are they all low-grade neoplasms?. Journal of Cutaneous Pathology, 35: 186-191.
Lambert I, Debiec-Rychter M, Guelinckx P, Hagemeijer A, Sciot R (2001) Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. Virchows Arch 438:509–512.
Ieremia E, Thway K. Myxoinflammatory fibroblastic sarcoma: morphologic and genetic updates. Arch Pathol Lab Med. 2014 Oct;138(10):1406-11.
Mansoor A, Fidda N, Himoe E, Payne M, Lawce H, Magenis RE (2004) Myxoinflammatory fibroblastic sarcoma with complex supernumerary ring chromosomes composed of chromosome 3 segments. Cancer Genet Cytogenet 152:61–65.
Suster D, Michal M, Huang H, Ronen S, Springborn S, Debiec-Rychter M, Billings SD, Goldblum JR, Rubin BP, Michal M, Suster S, Mackinnon AC. Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases. Mod Pathol. 2020 Dec;33(12):2520-2533.
Arbajian E, Hofvander J, Magnusson L, Mertens F. Deep sequencing of myxoinflammatory fibroblastic sarcoma. Genes Chromosomes Cancer. 2020 May;59(5):309-317.
Boland JM, Folpe AL. Hemosiderotic Fibrolipomatous Tumor, Pleomorphic Hyalinizing Angiectatic Tumor, and Myxoinflammatory Fibroblastic Sarcoma: Related or Not? Adv Anat Pathol. 2017 Sep;24(5):268-277.
Elco CP, Mariño-Enríquez A, Abraham JA, Dal Cin P, Hornick JL. Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link. Am J Surg Pathol. 2010 Nov;34(11):1723-7.
Zreik RT, Carter JM, Sukov WR, Ahrens WA, Fritchie KJ, Montgomery EA, Weiss SW, Folpe AL. TGFBR3 and MGEA5 rearrangements are much more common in "hybrid" hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study. Hum Pathol. 2016 Jul;53:14-24.
Liu H, Sukov WR, Ro JY. The t(1;10)(p22;q24) TGFBR3/MGEA5 translocation in pleomorphic hyalinizing angiectatic tumor, myxoinflammatory fibroblastic sarcoma, and hemosiderotic fibrolipomatous tumor. Arch Pathol Lab Med. (2019) 2:212–21.
Antonescu CR, Zhang L, Nielsen GP, Rosenberg AE, Dal Cin P, Fletcher CD. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011 Oct;50(10):757-64.
Kao YC, Ranucci V, Zhang L, Sung YS, Athanasian EA, Swanson D, Dickson BC, Antonescu CR. Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors. Am J Surg Pathol. 2017 Nov;41(11):1456-1465.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Derechos de autor 2024 Archivos de Patología